H.C. Wainwright assumed coverage of Iterum Therapeutics (ITRM) with a Buy rating and $9 price target Iterum is a pre-commercial stage company with an FDA approved product, the analyst tells investors in a research note. The firm says the company has the potential to deliver in urinary tract infections and infectious disease.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITRM: